Evidence map›Paper›PMID 40999465›Full record

ReviewWorld journal of surgical oncology2025

"Ewing's sarcoma of the duodenum: a rare gastrointestinal presentation": case report and review of literature.

Sujata Agrawal, Paramita Paul

Abstract readCase ReportsReview
In one paragraph

Review in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sujata AgrawalDepartment of Oncopathology, MPMMCC, TMC Varanasi, HBNI, Varanasi, UP, 221005, India.
Paramita PaulDepartment of Oncopathology, MPMMCC, TMC Varanasi, HBNI, Varanasi, UP, 221005, India. paulparamita84@yahoo.in.ORCID http://orcid.org/0000-0002-8725-1325

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ewing's sarcoma (ES) is exceptionally rare in the gastrointestinal tract, with only a few cases documented in the literature. We present a case of duodenal Ewing's sarcoma in a 44-year-old woman. The patient presented with severe abdominal pain, vomiting, and loss of appetite. Upper gastrointestinal endoscopy revealed a huge bulge in the first part of the duodenum (D1) wall, resulting in luminal narrowing in D1 and D2. A contrast-enhanced computed tomography scan corroborated the findings with no evidence of any distal metastasis. The patient is a known hypothyroid and had undergone hysterectomy five years back and cholecystectomy one year back. The patient underwent a Whipple procedure along with lymph node dissection. During surgery, a 4.5 cm mass was discovered in the D1 extending to the D2 segment of the duodenum. Histological examination showed a small round cell tumor in the submucosal region. The morphological differentials considered were gastrointestinal stromal tumor (GIST), poorly differentiated carcinoma, ES, neuroendocrine carcinoma (NEC) and lymphoma. Immunohistochemically the tumor cells tested positive for vimentin, NKX2.2, and CD99 (MIC2), and negative for markers of epithelial malignancy (AE1/AE3), lymphoma (CD45), melanoma (HMB45), NEC (INMS1,synaptophysin, chromogranin) and GIST (c-kit). One of the peri-duodenal lymph nodes showed a metastatic deposit. The case was diagnosed as Ewing's sarcoma (extra skeletal), TNM stage pT1 pN1. It was further ratified through fluorescence in situ hybridization (FISH), which showed a EWSR1 (22q12.1) gene rearrangement. A post-surgery PET scan indicated no residual disease. The patient had been receiving post-surgical adjuvant therapy and has completed four cycles of VAC (vincristine dactinomycin cyclophosphamide) and two cycles of VIME (Vincristine, Ifosfamide, Mesna, and Etoposide). The patient is disease-free with one-year follow-up. Follow up with PET scan is being performed at 3 months interval for the first year. The prognosis for Ewing's sarcoma in the gastrointestinal tract is not well-documented; however, a recent review of cases involving the small intestine suggests a poor prognosis. A follow up PET scanning every three months initially would help to target early recurrences and the interval can be increased after 2 years. Also emerging techniques like liquid biopsies is becoming increasingly relevant for detection of recurrences and metastasis.

Indexed as

Duodenal NeoplasmsSarcoma, EwingAdultFemaleHumansPrognosisDuodenumEwing sarcomaEWSR1-FLI1Fusion proteinSmall round cell sarcoma

Identifiers

PMID40999465
PMCPMC12465797

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.